Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide Combined with Short-Term Methotrexate for Major thalassemia

Status

Recruiting

Phases

Phase 3

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800017969

Enrollment

Unknown

Registered

2018-08-25

Start date

2018-09-01

Completion date

Unknown

Last updated

2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassemia

Interventions

Case series:post cyclophosphamide combined with methotrexate

Eligibility

Sex/Gender

All

Age

2 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. aged 2 to 40 years (including 2 and 40 years); 2. thalassemia major; 3. No HLA matched sibling or unrelated donor,or requiring prompt transplantation without finding HLA consistent donor opportunities; 4. sign informed consent.

Exclusion criteria

Exclusion criteria: 1. The physical fitness score is less than 70 points; 2. HCT specificity prognostic index (HCT-CT) was greater than 4 (including 4 points); 3. uncontrolled viral, bacterial, and fungal infections (progression of disease during antifungal therapy); 4. HIV seropositive; 5. malignant tumor; 6. pregnant and lactating women; 7. researchers believe that patients are not eligible for clinical trials.

Design outcomes

Secondary

Measure	Time frame
incidence of chronic GVHD;Survival;	—

Primary

Measure	Time frame
Accumulate accidence of aGVHD;Incidence of regimen-related mortality;Sustained engraftment;	—

Countries

China

Contacts

Public ContactBin Fu

Xiangya Hosptial of Central South University

xyfubin@126.com+86 0731 89753731

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026